MX2011008885A - Composiciones, sintesis y metodos para usar derivados de arilpiperazina. - Google Patents

Composiciones, sintesis y metodos para usar derivados de arilpiperazina.

Info

Publication number
MX2011008885A
MX2011008885A MX2011008885A MX2011008885A MX2011008885A MX 2011008885 A MX2011008885 A MX 2011008885A MX 2011008885 A MX2011008885 A MX 2011008885A MX 2011008885 A MX2011008885 A MX 2011008885A MX 2011008885 A MX2011008885 A MX 2011008885A
Authority
MX
Mexico
Prior art keywords
methods
arylpiperazine derivatives
synthesis
compositions
polypeptides
Prior art date
Application number
MX2011008885A
Other languages
English (en)
Inventor
Prabhu Prasad Mohapatra
Laxminarayan Bhat
Kouacou Adiey
Original Assignee
Reviva Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reviva Pharmaceuticals Inc filed Critical Reviva Pharmaceuticals Inc
Publication of MX2011008885A publication Critical patent/MX2011008885A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/341,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/361,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente invención provee derivados de arilpiperazina que pueden usarse ventajosamente para tratar esquizofrenia y psicosis relacionada tal corno trastorno maniaco agudo, trastorne bipolar, trastorno autista y depresión.
MX2011008885A 2009-02-26 2010-02-26 Composiciones, sintesis y metodos para usar derivados de arilpiperazina. MX2011008885A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15579109P 2009-02-26 2009-02-26
PCT/US2010/025687 WO2010099502A1 (en) 2009-02-26 2010-02-26 Compositions, synthesis, and methods of utilizing arylpiperazine derivatives

Publications (1)

Publication Number Publication Date
MX2011008885A true MX2011008885A (es) 2011-09-29

Family

ID=42631516

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008885A MX2011008885A (es) 2009-02-26 2010-02-26 Composiciones, sintesis y metodos para usar derivados de arilpiperazina.

Country Status (25)

Country Link
US (9) US8575185B2 (es)
EP (1) EP2400968B1 (es)
JP (1) JP5337259B2 (es)
KR (1) KR101705727B1 (es)
CN (2) CN106045936A (es)
AU (1) AU2010217772B2 (es)
BR (1) BRPI1009757B1 (es)
CA (1) CA2753599C (es)
CO (1) CO6430428A2 (es)
DK (1) DK2400968T3 (es)
ES (1) ES2605232T3 (es)
HK (1) HK1167240A1 (es)
HU (1) HUE031053T2 (es)
IL (1) IL214754A (es)
MX (1) MX2011008885A (es)
MY (1) MY161473A (es)
NZ (1) NZ595263A (es)
PH (1) PH12011501669B1 (es)
PL (1) PL2400968T3 (es)
PT (1) PT2400968T (es)
RU (1) RU2506262C2 (es)
SG (1) SG173842A1 (es)
UA (1) UA102730C2 (es)
WO (2) WO2010099502A1 (es)
ZA (1) ZA201106805B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010099502A1 (en) 2009-02-26 2010-09-02 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of utilizing arylpiperazine derivatives
KR101571670B1 (ko) * 2012-08-08 2015-11-25 주식회사 씨엠지제약 아리피프라졸을 포함하는 경구용 속용 필름 제제
WO2015157451A1 (en) 2014-04-08 2015-10-15 Reviva Pharmaceuticals, Inc. Methods for treating attention deficit hyperactivity disorder
CN107206007B (zh) * 2015-01-12 2021-08-10 雷维瓦药品公司 用于治疗肺高血压的方法
WO2016115150A1 (en) * 2015-01-12 2016-07-21 Reviva Pharmaceuticals Inc. Methods for treating psychosis associated with parkinson's disease
WO2016115144A1 (en) 2015-01-12 2016-07-21 Reviva Pharmaceuticals Inc. Methods for treating alzheimer's disease
GB201508864D0 (en) * 2015-05-22 2015-07-01 Glaxosmithkline Ip Dev Ltd Compounds
WO2017042837A2 (en) * 2015-09-11 2017-03-16 Sun Pharmaceutical Industries Limited Stable crystalline form of regadenoson
CN113912586B (zh) 2016-08-31 2023-04-07 江苏恒瑞医药股份有限公司 氧代吡啶酰胺类衍生物、其制备方法及其在医药上的应用
CN112618580A (zh) * 2020-12-30 2021-04-09 北京科拓恒通生物技术股份有限公司 鼠李糖乳杆菌Probio-M9及其制品用于制备治疗自闭症药物的用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274194A (en) 1963-03-29 1966-09-20 Miles Lab Quinazolinedione derivatives
FR2035749A1 (es) * 1969-02-06 1970-12-24 Bellon Labor Sa Roger
US3726979A (en) 1971-04-09 1973-04-10 E Hong Method of producing serotonin antagonism
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3879393A (en) 1973-06-18 1975-04-22 Miles Lab Derivatives of 1,3-disubstituted 2,4(1h,3h)-quinazolinediones
PH17194A (en) 1980-03-06 1984-06-19 Otsuka Pharma Co Ltd Novel carbostyril derivatives,and pharmaceutical composition containing the same
JPS58159480A (ja) 1982-03-17 1983-09-21 Chugai Pharmaceut Co Ltd 新規なフエニルピペラジン誘導体
JPS5970675A (ja) * 1982-10-15 1984-04-21 Otsuka Pharmaceut Co Ltd ベンゾオキサジン誘導体
JPS60169467A (ja) 1984-02-10 1985-09-02 Chugai Pharmaceut Co Ltd 新規なフエニルピペラジン誘導体
US4613598A (en) * 1984-03-13 1986-09-23 Mitsubishi Chemical Industries Limited Piperazine derivatives and their acid addition salts
US4716161A (en) 1984-04-17 1987-12-29 Mitsubishi Chemical Industries Limited Phenylpiperazine derivatives and their acid addition salts
US4711883A (en) 1985-09-30 1987-12-08 Ortho Pharmaceutical Corporation Substituted 3-(4-phenyl-1-piperazinyl)alkylquinazolin-2,4-(1H,3H) diones, methods of preparation, compositions and method of use
DK588486A (da) * 1985-12-09 1987-06-10 Otsuka Pharma Co Ltd Anvendelse af en forbindelse til behandling af hypoxi
US4803203A (en) 1986-11-05 1989-02-07 Warner-Lambert Company Phenyl and heterocyclic piperazinyl alkoxy-benzheterocyclic compounds as antipsychotic agents
FR2618437B1 (fr) 1987-07-23 1989-11-17 Rhone Poulenc Sante Nouveaux derives du benzopyranne, leur preparation et les medicaments qui les contiennent
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
DK203990D0 (da) 1990-08-24 1990-08-24 Novo Nordisk As Piperazinylderivater
US5234924A (en) * 1990-09-26 1993-08-10 Adir Et Compagnie Benzothiazine and benzothiazole compounds useful as analgesics
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
FR2680172B1 (fr) 1991-08-05 1993-11-19 Fabre Medicament Pierre Nouvelles piperazinylalcoyl-3 dihydro-2,3 4h-benzoxazine-1,3 ones-4 substituees, leur preparation et leur application en therapeutique.
JPH05331151A (ja) 1992-05-28 1993-12-14 Kyowa Hakko Kogyo Co Ltd キノキサリン−2−オン誘導体
US5994542A (en) 1995-11-14 1999-11-30 Sumitomo Chemical Company, Limited Process for producing 1-substituted tetrahydroquinazolines
FR2755690B1 (fr) 1996-11-08 1998-12-18 Adir Nouveaux derives aminomethyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE19743435A1 (de) 1997-10-01 1999-04-08 Merck Patent Gmbh Benzamidinderivate
SE0200301D0 (sv) * 2002-02-01 2002-02-01 Axon Biochemicals Bv Thio-carbostyril derivative
AU2003288755C1 (en) 2003-01-09 2015-02-19 Otsuka Pharmaceutical Co., Ltd. Process for preparing aripiprazole
CA2428237C (en) 2003-05-08 2010-07-20 Delmar Chemicals Inc. Process for the preparation of carbostyril derivatives
CN102000336A (zh) 2003-05-23 2011-04-06 大塚制药株式会社 用于治疗情感障碍的喹诺酮衍生物和情绪稳定剂
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
WO2005092841A1 (en) * 2004-03-23 2005-10-06 Pfizer Limited Compounds having beta-agonist activity
US7253168B2 (en) 2004-04-07 2007-08-07 Neurogen Corporation Substituted 1-benzyl-4-substituted piperazine analogues
US20090198059A1 (en) 2004-09-13 2009-08-06 Chava Satyanarayana Process for the preparation of polymorphs, solvates of aripiprazole using aripirazole acid salts
JP2007137818A (ja) 2005-11-17 2007-06-07 Taisho Pharmaceut Co Ltd 8−ヒドロキシ−2,4(1h,3h)−キナゾリンジオン誘導体
WO2008024481A2 (en) * 2006-08-24 2008-02-28 Concert Pharmaceuticals Inc. 3,4-dihydro-2 (1h) - quinolinone and 2 (1h)-quinolinone derivatives
JP4785881B2 (ja) * 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
NZ582124A (en) * 2007-05-21 2012-07-27 Reviva Pharmaceuticals Inc Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents
CA2709784A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2234555B1 (en) * 2008-01-25 2016-01-06 Medtronic ATS Medical, Inc. Cryoprobe clamp having transmurality assessment window
WO2009154993A1 (en) * 2008-05-27 2009-12-23 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using piperazine based antipsychotic agents
WO2010099502A1 (en) * 2009-02-26 2010-09-02 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of utilizing arylpiperazine derivatives
JP5331151B2 (ja) 2011-03-30 2013-10-30 日本発條株式会社 車両用シート

Also Published As

Publication number Publication date
NZ595263A (en) 2013-06-28
US20150005298A1 (en) 2015-01-01
US8431570B2 (en) 2013-04-30
US20100216783A1 (en) 2010-08-26
US20160229821A1 (en) 2016-08-11
US8188076B2 (en) 2012-05-29
EP2400968B1 (en) 2016-09-28
BRPI1009757A2 (pt) 2016-03-15
EP2400968A1 (en) 2012-01-04
EP2400968A4 (en) 2012-08-01
US8461154B2 (en) 2013-06-11
US8575185B2 (en) 2013-11-05
ES2605232T3 (es) 2017-03-13
AU2010217772A1 (en) 2011-10-20
US20150166493A1 (en) 2015-06-18
US8859552B2 (en) 2014-10-14
PT2400968T (pt) 2016-12-09
RU2506262C2 (ru) 2014-02-10
IL214754A0 (en) 2011-11-30
US9975862B2 (en) 2018-05-22
IL214754A (en) 2014-05-28
BRPI1009757B1 (pt) 2020-01-14
HUE031053T2 (en) 2017-06-28
US20100222359A1 (en) 2010-09-02
JP5337259B2 (ja) 2013-11-06
CN102413830A (zh) 2012-04-11
DK2400968T3 (da) 2017-01-02
PH12011501669B1 (en) 2014-02-13
HK1167240A1 (zh) 2012-11-23
KR20120013306A (ko) 2012-02-14
CA2753599C (en) 2017-03-14
KR101705727B1 (ko) 2017-02-10
AU2010217772B2 (en) 2014-10-23
CA2753599A1 (en) 2010-09-02
JP2012519182A (ja) 2012-08-23
WO2010099503A1 (en) 2010-09-02
US20120220574A1 (en) 2012-08-30
US9604944B2 (en) 2017-03-28
US8980883B2 (en) 2015-03-17
WO2010099502A1 (en) 2010-09-02
US20140155392A1 (en) 2014-06-05
MY161473A (en) 2017-04-14
US20120220579A1 (en) 2012-08-30
RU2011139154A (ru) 2013-04-10
ZA201106805B (en) 2013-02-27
UA102730C2 (uk) 2013-08-12
PL2400968T3 (pl) 2017-04-28
CN106045936A (zh) 2016-10-26
SG173842A1 (en) 2011-09-29
US20170327477A1 (en) 2017-11-16
CO6430428A2 (es) 2012-04-30
US9255076B2 (en) 2016-02-09

Similar Documents

Publication Publication Date Title
MX2011008885A (es) Composiciones, sintesis y metodos para usar derivados de arilpiperazina.
MX359475B (es) Composiciones antitranspirantes y desodorantes.
MX2012007367A (es) Compuestos substituidos de imidazopiridinilo-aminopiridina.
BRPI0908926A2 (pt) Compostos de policarbonato-poliorganosiloxano e/ou poliuretano-poliorganosiloxano
UA99936C2 (en) Biaryl substituted azabicyclic alkane derivatives
GEP20125652B (en) cMET INHIBITORS
MX2011009369A (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2011006959A (es) Compuestos substituidos de 5,6-dihidro-6-fenilbenzo [f] isoquinolina-2-amina.
MX2010008714A (es) Derivados de amida como moduladores alostericos positivos y metodos de uso de los mismos.
MX2009012506A (es) Composiciones, sintesis, y metodos para utilizar agentes antipsicoticos atipicos basados en quinolinona.
MX2010001865A (es) Composiciones para el cuidado personal que comprenden complejos de colorante-polimero.
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
NZ713396A (en) Engineered phenylalanine ammonia lyase polypeptides
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
GB0916338D0 (en) Branched addition copolymers in curing systems
MY157192A (en) Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands
MX340807B (es) Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.
MX2011008825A (es) 3-aminoisoxazolopiridinas sustituidas como moduladores de kcnq2/3.
HK1141790A1 (es)
MX348325B (es) Composicion que contiene galacto-oligosacarido y un metodo para producirla.
MY156769A (en) Heat-aging-resistant polyamides
MX342947B (es) Tratamiento de diabetes tipo 2.
MX2011008662A (es) 2-mercapto-3-aminopiridinas sustituidas como moduladores de kcnq2/3.
MX2011009338A (es) 3-amino-2-mercaptoquinolinas sustituidas como moduladores de kcnq2/3.
MX2011008850A (es) Derivados de piperidina como antagonistas del receptor de neuroquinina 3 (nk3).

Legal Events

Date Code Title Description
FG Grant or registration